Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

Galloway, Gantt P.; Koch, Monika; Cello, Ryan; Smith, David E.
January 2005
BMC Psychiatry;2005, Vol. 5, p18
Academic Journal
Background: Naltrexone is an effective medication for treatment of alcohol dependence, but its efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of naltrexone may increase adherence. Methods: A single site, 6-week open label study was conducted with 16 alcohol dependent subjects each receiving 300 mg of Naltrexone Depot by intramuscular injection. The main outcomes were safety and tolerability of the Naltrexone Depot formulation, blood levels of naltrexone and its main metabolite 6-beta naltrexol, and self-reported alcohol use. All subjects received weekly individual counseling sessions. Results: The medication was well tolerated with 88% of subjects completing the 6-week trial. The most common side effect experienced was injection site complications. There were no serious adverse events. Subjects had naltrexone and 6-beta-naltrexol concentrations throughout the trial with mean values ranging from 0.58 ng/mL to 2.04 ng/mL and 1.51 ng/mL to 5.52 ng/mL, respectively, at each sampling time following administration. Compared to baseline, subjects had significantly reduced number of drinks per day, heavy drinking days and proportion of drinking days. Conclusion: Naltrexone Depot is safe and well tolerated in alcoholics and these findings support the further investigation of its utility in larger double-blind placebo controlled trials.


Related Articles

  • PI-82. Hayes, S.; Farrell, C.; Dunbar, J.; Turncliff, R. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP28 

    Background: Naltrexone (NTX) is used in the treatment of alcohol and opioid dependency. While oral NTX must be given daily, long-acting naltrexone (LA-NTX) was designed to provide continuous exposure to NTX for 1 month with a single IM injection.Aims: To characterize the population...

  • What Place Does Naltrexone Have in the Treatment of Alcoholism? Rohsenow, Damaris J. // CNS Drugs;2004, Vol. 18 Issue 9, p547 

    Despite two recent negative trials, most controlled clinical studies have found that when naltrexone is added to substance abuse treatment or counselling, significantly less heavy drinking is done by the patients who are willing to take most of the prescribed naltrexone. Naltrexone also reduces...

  • AN OPEN LABEL TRIAL OF NALTREXONE VERSUS DISULFIRAM IN ELDERLY PATIENTS WITH ALCOHOL DEPENDENCE. De Sousa, Avinash; Jagtap, Jyoti // Journal of Pakistan Psychiatric Society;2009, Vol. 6 Issue 2, p85 

    Objectives: This study aims to compare the efficacy of Disulfiram (DSF) and Naltrexone (NTX) for preventing alcoholic relapse in elderly patients in routine clinical practice. Design: Open label trial of naltrexone versus disulfiram. Place and duration of study: The study was conducted between...

  • Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for I Month in Rats. Bartus, Raymond T.; Emerich, Dwaine F.; Hotz, Joyce; Blaustein, Marc; Dean, Reginald L.; Perdomo, Brigido; Basile, Anthony S. // Neuropsychopharmacology;Nov2003, Vol. 28 Issue 11, p1973 

    While oral naltrexone is effective in treating alcohol and opiate dependencies, poor patient adherence and widely fluctuating plasma levels limit its efficacy. To overcome these problems, an extended-release formulation of naltrexone (Vivitrex®) was developed by encapsulating naltrexone into...

  • Heavy drinking can be reduced by injection with naltrexone.  // Nursing Standard;5/18/2005, Vol. 19 Issue 36, p18 

    Reports on research which found that long-acting naltrexone can be of benefit in the treatment of alcohol dependence. Results of a randomized trial of long-acting injectable naltrexone.

  • Using pharmacokinetic/pharmacodynamic priciples to optimize carbapenem use.  // Formulary;Jul2007 Supplement, Vol. 42, p11 

    The article presents the standards set to test the most effective and potent regimens in the U.S. The main pharmacokinetic (PK)/PD parameters are the ratio of the peak drug concentration to the minimum inhibitory concentration (TMIC) and the duration of time that drug concentrations remain above...

  • Naltrexone in the Treatment of Alcohol Dependence. Krystal, John H.; Cramer, Joyce A.; Krol, William F.; Kirk, Gail F.; Rosenheck, Robert A. // New England Journal of Medicine;12/13/2001, Vol. 345 Issue 24, p1734 

    Background: Although naltrexone, an opiate-receptor antagonist, has been approved by the Food and Drug Administration for the treatment of alcohol dependence, its efficacy is uncertain. Methods: We conducted a multicenter, double-blind, placebo-controlled evaluation of naltrexone as an adjunct...

  • Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. van den Brink, Wim; Aubin, Henri-Jean; Bladström, Anna; Torup, Lars; Gual, Antoni; Manne, Karl // Alcohol & Alcoholism;Sep/Oct2013, Vol. 48 Issue 5, p570 

    Aims: The aim of the study was to investigate the efficacy and safety of as-needed use of nalmefene 18 mg versus placebo in reducing alcohol consumption in patients who did not reduce their alcohol consumption after an initial assessment, i.e. the pooled subgroup of patients with at least a high...

  • NALTREXONE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p580 

    The article presents information on naltrexone, a narcotic antagonist, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics